Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1993 3
1994 6
1995 3
1996 48
1997 176
1998 299
1999 365
2000 407
2001 453
2002 439
2003 445
2004 461
2005 540
2006 543
2007 550
2008 544
2009 504
2010 511
2011 557
2012 548
2013 557
2014 510
2015 457
2016 419
2017 370
2018 365
2019 386
2020 281
Text availability
Article attribute
Article type
Publication date

Search Results

9,931 results
Results by year
Filters applied: . Clear all
Page 1
The Expanding Therapeutic Perspective of CCR5 Blockade.
Vangelista L, Vento S. Vangelista L, et al. Front Immunol. 2018 Jan 12;8:1981. doi: 10.3389/fimmu.2017.01981. eCollection 2017. Front Immunol. 2018. PMID: 29375583 Free PMC article. Review.
CCR5 and its interaction with chemokine ligands have been crucial for understanding and tackling HIV-1 entry into target cells. ...Therefore, CCR5 antagonism and gene-edited knockout of the receptor gained growing interest for the therapeutic role that CCR5 b
CCR5 and its interaction with chemokine ligands have been crucial for understanding and tackling HIV-1 entry into target cells. ...Th
CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy.
Allers K, Schneider T. Allers K, et al. Curr Opin Virol. 2015 Oct;14:24-9. doi: 10.1016/j.coviro.2015.06.007. Epub 2015 Jul 1. Curr Opin Virol. 2015. PMID: 26143158 Review.
A homozygous Δ32 mutation in the CCR5 gene prevents CCR5 cell surface expression and thus confers resistance to infection with CCR5-tropic HIV strains. ...Therefore, intense work is currently being carried out on CCR5 gene-editing tools to develop cura …
A homozygous Δ32 mutation in the CCR5 gene prevents CCR5 cell surface expression and thus confers resistance to infection with …
Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme.
Kranjc MK, Novak M, Pestell RG, Lah TT. Kranjc MK, et al. Radiol Oncol. 2019 Nov 20;53(4):397-406. doi: 10.2478/raon-2019-0057. Radiol Oncol. 2019. PMID: 31747383 Free PMC article. Review.
There are important CCL5 and CCR5 structure and signalling mechanisms in glioblastoma. In addition, the CCL5/CCR5 axis directs infiltration and interactions with monocytes/macrophages and mesenchymal stem cells, comprising glioblastoma stem cell niches. Conclusions …
There are important CCL5 and CCR5 structure and signalling mechanisms in glioblastoma. In addition, the CCL5/CCR5 axis directs …
Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer.
Aldinucci D, Casagrande N. Aldinucci D, et al. Int J Mol Sci. 2018 May 16;19(5):1477. doi: 10.3390/ijms19051477. Int J Mol Sci. 2018. PMID: 29772686 Free PMC article. Review.
C-C chemokine receptor type 5 (CCR5) is expressed in T cells, macrophages, other leukocytes, and certain types of cancer cells. The interaction between CCL5 and CCR5 plays an active role in recruiting leukocytes into target sites. This review summarizes recent infor …
C-C chemokine receptor type 5 (CCR5) is expressed in T cells, macrophages, other leukocytes, and certain types of cancer cells. The i …
CCR5 Revisited: How Mechanisms of HIV Entry Govern AIDS Pathogenesis.
Brelot A, Chakrabarti LA. Brelot A, et al. J Mol Biol. 2018 Aug 17;430(17):2557-2589. doi: 10.1016/j.jmb.2018.06.027. Epub 2018 Jun 19. J Mol Biol. 2018. PMID: 29932942 Review.
More recently, the apparent HIV cure in a patient transplanted with hematopoietic stem cells devoid of functional CCR5 rekindled the interest for inactivating CCR5 through gene therapy and pharmacological approaches. ...In this article, we propose to review the key …
More recently, the apparent HIV cure in a patient transplanted with hematopoietic stem cells devoid of functional CCR5 rekindled the …
CCR5 structural plasticity shapes HIV-1 phenotypic properties.
Colin P, Zhou Z, Staropoli I, Garcia-Perez J, Gasser R, Armani-Tourret M, Benureau Y, Gonzalez N, Jin J, Connell BJ, Raymond S, Delobel P, Izopet J, Lortat-Jacob H, Alcami J, Arenzana-Seisdedos F, Brelot A, Lagane B. Colin P, et al. PLoS Pathog. 2018 Dec 6;14(12):e1007432. doi: 10.1371/journal.ppat.1007432. eCollection 2018 Dec. PLoS Pathog. 2018. PMID: 30521629 Free PMC article.
The different binding levels of gp120s also correspond to differences in their capacity to bind CCR5 dimers/oligomers. Mutating the CCR5 dimerization interface changed conformation of the CCR5 homodimers and modulated differentially the binding of distinct gp …
The different binding levels of gp120s also correspond to differences in their capacity to bind CCR5 dimers/oligomers. Mutating the …
CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape.
Hütter G, Bodor J, Ledger S, Boyd M, Millington M, Tsie M, Symonds G. Hütter G, et al. Viruses. 2015 Jul 27;7(8):4186-203. doi: 10.3390/v7082816. Viruses. 2015. PMID: 26225991 Free PMC article. Review.
Allogeneic transplantation with CCR5-delta 32 (CCR5-d32) homozygous stem cells in an HIV infected individual in 2008, led to a sustained virus control and probably eradication of HIV. ...The first one is to use a CCR5 negative cell source e.g., hematopoietic …
Allogeneic transplantation with CCR5-delta 32 (CCR5-d32) homozygous stem cells in an HIV infected individual in 2008, led to a …
CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma.
Umansky V, Blattner C, Gebhardt C, Utikal J. Umansky V, et al. Cancer Immunol Immunother. 2017 Aug;66(8):1015-1023. doi: 10.1007/s00262-017-1988-9. Epub 2017 Apr 5. Cancer Immunol Immunother. 2017. PMID: 28382399 Review.
An increased CCR5 expression on MDSCs was associated with elevated concentrations of CCR5 ligands in melanoma microenvironment. ...Targeting CCR5/CCR5 ligand signaling via a fusion protein mCCR5-Ig, which selectively binds and neutralizes all three …
An increased CCR5 expression on MDSCs was associated with elevated concentrations of CCR5 ligands in melanoma microenvironment …
CCR5(+) Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions.
Blattner C, Fleming V, Weber R, Himmelhan B, Altevogt P, Gebhardt C, Schulze TJ, Razon H, Hawila E, Wildbaum G, Utikal J, Karin N, Umansky V. Blattner C, et al. Cancer Res. 2018 Jan 1;78(1):157-167. doi: 10.1158/0008-5472.CAN-17-0348. Epub 2017 Oct 31. Cancer Res. 2018. PMID: 29089297 Free article.
Tumor-infiltrating CCR5(+) MDSCs displayed higher immunosuppressive activity than their CCR5(-) counterparts. Upregulation of CCR5 expression on CD11b(+)Gr1(+) myeloid cells was induced in vitro by CCR5 ligands and other inflammatory factors. In melano …
Tumor-infiltrating CCR5(+) MDSCs displayed higher immunosuppressive activity than their CCR5(-) counterparts. Upregulation of …
HEK293T Cells Are Heterozygous for CCR5 Delta 32 Mutation.
Qi C, Jia X, Lu L, Ma P, Wei M. Qi C, et al. PLoS One. 2016 Apr 4;11(4):e0152975. doi: 10.1371/journal.pone.0152975. eCollection 2016. PLoS One. 2016. PMID: 27042825 Free PMC article.
C-C chemokine receptor 5 (CCR5) is a receptor for chemokines and a co-receptor for HIV-1 entry into the target CD4+ cells. CCR5 delta 32 deletion is a loss-of-function mutation, resistant to HIV-1 infection. ...Surprisingly, we found that HEK293T cells are heterozyg …
C-C chemokine receptor 5 (CCR5) is a receptor for chemokines and a co-receptor for HIV-1 entry into the target CD4+ cells. CCR5
9,931 results
Jump to page
Feedback